What is the definition of Myxoid Liposarcoma?

Myxoid liposarcoma is a subtype of liposarcoma, tumors that arise in the body’s fat tissue. Other categories of liposarcoma include well-differentiated; dedifferentiated; round cell; and pleomorphic. Round cell and myxoid liposarcomas are sometimes grouped together into one category known as myxoid/round cell liposarcoma (MRCLS). In adults, liposarcomas are the most common type of soft tissue sarcoma. The cause of liposarcomas is not well-established but trauma has been implicated in some cases. Myxoid liposarcomas generally arise in the lower extremities. Symptoms may vary depending on the location of the tumor but may include swelling; decreased range of motion; numbness; fatigue; abdominal pain; weight loss; nausea; and vomiting. Many patients with liposarcoma have no symptoms until the tumor is large and interferes with neighboring structures. When possible, surgical removal is the preferred treatment. In some cases, additional therapy may be indicated. The prognosis is generally favorable for those with a low grade myxoid liposarcoma with a small percentage of round cells. A significant round cell component is associated with a poorer prognosis.  Although these tumors rarely spread, they can recur if not completely removed. 

What are the alternative names for Myxoid Liposarcoma?

  • Myxoid/round cell liposarcoma
  • Myxoliposarcoma
  • Condition: Brain Metastasis from Soft Tissue Sarcomas
  • Journal: Anticancer research
  • Treatment Used: Combined Surgery and Radiotherapy
  • Number of Patients: 509
  • Published —
This study tested the safety and efficacy of using a combined surgery and radiotherapy regimen to treat patients with brain metastases that they acquired from their soft tissue sarcoma.
  • Condition: High-Risk Soft Tissue Sarcomas
  • Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Treatment Used: Add-on Chemotherapy
  • Number of Patients: 287
  • Published —
The study researched the outcomes of chemotherapy in treating high-risk soft tissue sarcomas.